Please wait a minute...
Journal of ZheJiang University(Medical Science)  2016, Vol. 45 Issue (5): 501-507    DOI: 10.3785/j.issn.1008-9292.2016.09.08
    
Progress on anti-tumor molecular mechanisms of dihydroartemisinin
CAO Peng, LENG Dongjin, LI Ying, ZHANG Ziwei, LIU Lei, LI Xiaoyan
College of Life Science, Northeast Forest University, Harbin 150040, China
Download: HTML (   PDF(762KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Artemisinin is an anti-malarial drug with poor water solubility and oral absorption; so a variety of derivatives based on the parent nucleus have been developed. Compared with artemisinin, dihydroartemisinin (DHA) has a stronger anti-malaria activity, and has the advantages of high metabolic rate and better water solubility. Recent studies have discovered that DHA has a good inhibitory effect on tumor cells, which is closely related to the peroxide bridge in its molecular structure. Since tumor cells need more Fe3+ than normal cells, there are a large number of transferrin receptors on the tumor cell membrane. DHA can break the peroxide bridge in the presence of Fe2+, and the free radicals generated can play its lethal effect on tumor cells. In addition, DHA can promote endocytosis of transferrin receptor, and thus prevent cancer cells from taking Fe3+ from microenvironment. This article reviews the anti-tumor molecular mechanism of DHA, including accelerating oxidative damage, inducing apoptosis, inhibiting the growth, proliferation and invasion of tumor cells, reversing tumor multidrug resistance.



Key wordsArtemisinin/analogs &      derivatives      Artemisinin/pharmacology      Antineoplastic drugs (TCD)/therapeutic use      Apoptosis/drug effects      Cell proliferation/drug effects      Neoplasm invasiveness      Neoplasm metastasis      Review     
Received: 23 October 2015      Published: 25 September 2016
CLC:  R966  
Cite this article:

CAO Peng, LENG Dongjin, LI Ying, ZHANG Ziwei, LIU Lei, LI Xiaoyan. Progress on anti-tumor molecular mechanisms of dihydroartemisinin. Journal of ZheJiang University(Medical Science), 2016, 45(5): 501-507.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2016.09.08     OR     http://www.zjujournals.com/med/Y2016/V45/I5/501


双氢青蒿素抗肿瘤分子生物学机制研究进展

青蒿素作为抗疟特效药在临床应用中存在水溶性小、口服效果差等缺点,因此研究人员开发了保留其母核的多种衍生物。其中双氢青蒿素(DHA)的抗疟活性更强,且具有在体内代谢速度快、水溶性好等优点,同时DHA对肿瘤细胞也有良好的抑制效果,且其分子生物学作用机制与自身结构中的过氧桥密切相关。由于肿瘤细胞比正常细胞需要摄取更多的铁离子,因此肿瘤细胞膜上存在大量的转铁蛋白受体。DHA能在亚铁离子的存在下使过氧桥发生断裂,产生自由基从而对肿瘤细胞发挥杀伤作用,并能使转铁蛋白受体发生内吞,阻止肿瘤细胞从外界摄入必需的铁离子。本文主要从DHA加速细胞氧化损伤、诱导肿瘤细胞凋亡、抑制肿瘤细胞生长增殖和侵袭转移以及逆转肿瘤细胞多药耐药等方面对其抗肿瘤的分子生物学机制进行综述。


关键词: 青蒿素/类似物和衍生物,  青蒿素/药理学,  抗肿瘤药(中药)/治疗应用,  细胞凋亡/药物作用,  细胞增殖/药物作用,  肿瘤侵润,  肿瘤转移,  综述 
[[1]]   SIEGEL R, NAISHADHAM D, JEMAL A.Cancer statistics, 2012[J].C A Cancer J Clin, 2012, 62(1):10-29.
[[2]]   HOLOHAN C, VAN SCHAEYBROECK S, LONGLEY D B, et al.Cancer drug resistance:an evolving paradigm[J].Nat Rev Cancer, 2013, 13(10):714-726.
[[3]]   BURAGOHAIN P, SAIKIA B, SURINENI N, et al.Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction[J].Bioorg Med Chem Lett, 2014, 24(1):237-239.
[[4]]   KUWANO K.Involvement of epithelial cell apoptosis in interstitial lung diseases[J].Intern Med, 2008, 47(5):345-353.
[[5]]   CARO J T, MARÍN L M, IAZBIK M C, et al.Markers of iron metabolism in retired racing greyhounds with and without osteosarcoma[J].Vet Clin Pathol, 2013, 42(3):360-363.
[[6]]   ONTIKATZE T, RUDNER J, HANDRICK R, et al.Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells[J].Front Oncol, 2014, 4:116.
[[7]]   LU Y Y, CHEN T S, WANG X P, et al.Single-cell analysis of dihydroartemisinin-induced apoptosis through reactive oxygen species-mediated caspase-8 activation and mitochondrial pathway in ASTC-a-1 cells using fluorescence imaging techniques[J].J Biomed Opt, 2010, 15(4):046028.
[[8]]   BA Q, ZHOU N, DUAN J, et al.Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1[J/OL].PLoS One, 2012, 7(8):e42703.
[[9]]   ASIF M, IQBAL M A, HUSSEIN M A, et al.Human colon cancer targeted pro-apoptotic, anti-metastatic and cytostatic effects of binuclear Silver (I) eN-Heterocyclic carbene (NHC) complexes[J].Eur J Med Chem, 2015, 108:177-187.
[[10]]   LU J J, CHEN S M, ZHANG X W, et al.The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells[J].Invest New Drugs, 2011, 29(6):1276-1283.
[[11]]   LU M, SUN L, ZHOU J, et al.Dihydroartemisinin-induced apoptosis is associated with inhibition of sarco/endoplasmic reticulum calcium ATPase activity in colorectal cancer[J].Cell Biochem Biophys, 2015, 73(9):137-145.
[[12]]   GAO X, LUO Z, XIANG T, et al.Dihydroartemisinin induces endoplasmic reticulum stress-mediated apoptosis in HepG2 human hepatoma cells[J].Tumori, 2011, 97(6):771-780.
[[13]]   CHEN M, CHEN T S, LU Y Y, et al.Dihydroarteminsin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells[J].Pathol Oncol Res, 2012, 18(4):809-816.
[[14]]   DU X X, LI Y J, WU C L, et al.Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin[J].Biomed Pharmacother, 2013, 67(5):417-424.
[[15]]   CHEN S S, HU W, WANG Z, et al.p8 attenuates the apoptosis indueced by dihydroartemisinin in cancer cells through promoting autophagy[J].Cancer Biol Ther, 2015, 16(5):770-779.
[[16]]   JIA G, KONG R, MA Z B, et al.The activation of c-Jun NH2-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells[J].J Exp Clin Cancer Res, 2014, 33:8.
[[17]]   AUNG W, SOGAWA C, FURUKAWA T, et al.Anticancer effect of dihydroartemisinin (D) HAin a pancreatic tumor model evaluated by conventional methods and optical imaging[J].Anticancer Res, 2011, 31(5):1549-1558.
[[18]]   LU M, SUN L, ZHOU J, et al.Dihydroartemisinin induces apoptosis in colorectal cancer cells through the mitochondria-dependent pathway[J].Tumor Biol, 2014, 35(6):5307-5314.
[[19]]   CABELLO C M, LAMORE S D, BAIR W B 3RD, et al.The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis[J].Invest New Drug, 2012, 30(4):1289-1301.
[[20]]   JI Y, ZHANG Y C, PEI L B, et al.Anti-tumor effects of dihydroartemisinin on human osteosarcoma[J].Mol Cell Biochem, 2011, 351(1-2):99-108.
[[21]]   LI Y J, ZHOU J H, DU X X, et al.Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells[J].Cell Physiol Biochem, 2014, 33(5):1527-1536.
[[22]]   AN F F, LIU Y C, ZHANG W W, et al.Dihydroartemisinine enhances dictamnine-induced apoptosis via a caspase dependent pathway in human lung adenocarcinoma A549 cells[J].Asian Pac J Cancer PREV, 2013, 14(10):5895-5900.
[[23]]   HE Q, SHI J, SHEN X L, et al.Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells[J].Cancer Biol Ther, 2010, 9(10):819-824.
[[24]]   KONG R, JIA G, CHENG Z X, et al.Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5[J/OL].PLoS One, 2012, 7(5):e37222.
[[25]]   WANG S J, GAO Y, CHEN H, et al.Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo[J].Cancer Lett, 2010, 293(1):99-108.
[[26]]   MAGENTA D, SANGIOVANNI E, BASILICO N, et al.Inhibition of metalloproteinase-9 secretion and gene expression by artemisinin derivatives[J].Acta Trop, 2014, 140:77-83.
[[27]]   FENG X, LI L, JIANG H, et al.Dihydroartemisinin potentiates the anticancer effect of cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer cells:involvement of apoptosis and autophagy[J].Biochem Biophys Res Commun, 2014, 444(3):376-381.
[[28]]   ODAKA Y, XU B, LUO Y, et al.Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells[J].Carcinogenesis, 2014, 35(1):192-200.
[[29]]   LIU Y, WANG W, XU J, et al.Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/β-catenin signaling[J].Oncol Rep, 2013, 30(4):1723-1730.
[[30]]   MI Y J, GENG G J, ZOU Z Z, et al.Dihydroartemisinin inhibits glucose uptake and cooperates with glycolysis inhibitor to induce apoptosis in non-small cell lung carcinoma cells[J/OL].PloS One, 2015, 10(3):e0120426.
[[31]]   ZHANG S, MA Y, JIANG J, et al.Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells[J].Oncol Lett, 2014, 7(5):1375-1380.
[[32]]   HWANG Y P, YUN H J, KIM H G, et al.Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKC a/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms[J].Biochem Pharmacol, 2010, 79(12):1714-1726.
[[33]]   HU C J, ZHOU L, CAI Y.Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2[J].Cancer Biol Ther, 2014, 15(3):279-288.
[[34]]   WU B, HU K, LI S, et al.Dihydroartiminisin inhibits the growth and metastasis of epithelial ovarian cancer[J].Oncol Rep, 2012, 27(1):101-108.
[[35]]   D'ALESSANDRO S, BASILICO N, CORBETT Y, et al.Hypoxia modulates the effect of dihydroartemisinin on endothelial cells[J].Biochem Pharmacol, 2011, 82(5):476-484.
[[36]]   WANG S J, SUN B, CHENG Z X, et al.Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway[J].Cancer Chemoth Pharmacol, 2011, 68(6):1421-1430.
[[37]]   HOOFT VAN HUIJSDUIJNEN R, GUY R K, CHIBALE K, et al.Anticancer properties of distinct antimalarial drug classes[J/OL].PLoS One, 2013, 8(12):e82962.
[[38]]   ZHAO C, GAO W, CHEN T.Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine[J/OL].Apoptosis, 2014, 19(4):668-681.
[[39]]   CHEN T, CHEN M, CHEN J.Ionizing radiation potentiates dihydroartemisinin-induced apoptosis of A549 Cells via a caspase-8-dependent pathway[J/OL].PLoS One, 2013, 8(3):e59827.
[[40]]   LIU Y, LIU Z, SHI J, et al.Synthesis and cytotoxicity of novel 10-substituted dihydroartemisinin derivatives containing N-arylphenyl-ethenesulfonamide groups[J].Molecules, 2013, 18(3):2864-2877.
[[41]]   DAI L, WANG Y L, DENG L H, et al.Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer[J].Sci Rep, 2014, 4:5871.
[[42]]   RIGHESCHI C, CORONNELLO M, MASTRANTONI A, et al.Strategy to provide a useful solution to effective delivery of dihydroartemisinin:development, characterization and in vitro studies of liposomal formulations[J].Colloids Surf B Biointerfaces, 2014, 116:121-127.
[[43]]   LIU L, WEI Y, ZHAI S, et al.Dihydroartemisinin and transferrin dual-dressed nano-graphene oxide for a pH-triggered chemotherapy[J].Biomaterials, 2015, 62:35-46.
[1] FENG Mengyu,ZHANG Taiping,ZHAO Yupei. Present situation and prospect of enhanced recovery after surgery in pancreatic surgery[J]. Journal of ZheJiang University(Medical Science), 2017, 46(6): 666-674.
[2] XU Jingjing, TAN Yanbin, ZHANG Minming. Medical imaging in tumor precision medicine: opportunities and challenges[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 455-461.
[3] PAN Jingying, HE Mengye, KE Wei, HU Menglin, WANG Meifang, SHEN Peng. Advances on correlation of PET-CT findings with breast cancer molecular subtypes, treatment response and prognosis[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 473-480.
[4] ZHANG Siying, CHEN Feng. Research progress of CT/MRI parametric response map in precision evaluation of therapeutic response of cancer patients[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 468-472.
[5] PAN Yao, CHEN Jieyu, YU Risheng. Accurate imaging diagnosis and evaluation of pancreatic cancer[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 462-467.
[6] BIAN Wei, YAO Yuan, ZHANG Haijin, YE Xiaoqian, ZHANG Minming. Application of CT scan in diagnosis of pathological type and origin of metastatic ovarian tumors[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 546-551.
[7] WANG Mengyan, ZHU Biao. Research progress on genes mutations related to sulfa drug resistance in Pneumocystis jirovecii[J]. Journal of ZheJiang University(Medical Science), 2017, 46(5): 563-569.
[8] JIANG Yiqian, GUO Qingmin, GU Jianzhong, XU Xiaoping, AN Suhong, SU Fang, BAO Yanhong, HUANG Changxin, GUAN Xiaoxiang. Effect of microRNA-29b on proliferation and migration of breast cancer cells and its molecular mechanism[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 349-356.
[9] LI Yandie, LU Meiping. Progress on the study of NLRP3 inflammasome in autoinflammatory diseases of children[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 449-453.
[10] FENG Xuewen, CHEN Zhicai, ZHONG Genlong, LOU Min. Safety of tirofiban in patients with acute cerebral infarct receiving endovascular therapy[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 397-404.
[11] CHEN Zhiqiang, WANG Ying, MI Xianjun, DUAN Lifeng, CHEN Ang, HUANG Huayong. Volume of 4% neutral buffered formaldehyde affects the results of HER2 gene detected by fluorescence in situ hybridization in primary invasive breast cancer[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 439-444.
[12] TIAN Hua, CHEN Yang, ZHAO Jiangang, LIU Daren, LIANG Gang, GONG Weihua, CHEN Li, WU Yulian. Effects of siRNAs targeting CD97 immune epitopes on biological behavior in breast cancer cell line MDA-MB231[J]. Journal of ZheJiang University(Medical Science), 2017, 46(4): 341-348.
[13] SHEN Dan, WANG Fangfang, JIANG Zhou, QU Fan. Long-term effects of polycystic ovary syndrome on the offspring[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 300-304.
[14] ZHANG Xiaoqun, WANG Qiwen, WANG Xin, XU Xiaolei, ZHU Jianhua. Comparison of limus-eluting stent with paclitaxel-eluting stent for patients with coronary small vessel disease:a systematic review and meta-analysis[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 305-314.
[15] FU Xiaohua, XU Weihai, QIU Shengchun, SHU Jing. Research progress on the relationship of brown adipose tissue with polycystic ovary syndrome[J]. Journal of ZheJiang University(Medical Science), 2017, 46(3): 315-320.